Ainos, Inc.

Ainos, Inc., incorporated in Texas in 1984, is a dual-platform company focused on artificial intelligence-based smell technologies and immune therapeutics. The company's main strategic focus is commercializing its proprietary scent digitization platform, AI Nose. Concurrently, Ainos develops therapeutic assets from its low-dose oral interferon program, VELDONA®. AI Nose is an AI-based electronic olfaction system that combines gas sensor arrays with proprietary artificial intelligence models, called a smell language model (SLM), to convert scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format. Initially developed for healthcare settings, including point-of-care testing (POCT), AI Nose's sensor architecture, data models, and system calibration were shaped by these early applications. The company is now expanding AI Nose into industrial environments for real-time environmental sensing, anomaly detection, and operational monitoring. Current and planned industrial uses include semiconductor manufacturing, robotics, and smart manufacturing. Ainos believes AI Nose's scent digitization architecture is adaptable across various industrial and non-industrial sectors. Ainos is advancing AI Nose through partner-led deployments, focusing on platform scalability, data-driven performance improvement, and integration into existing industrial ecosystems. The company aims to expand scent's role as a machine-readable data alongside vision and sound. Separately, Ainos continues to develop VELDONA®, its low-dose oral interferon platform, for selected rare, autoimmune, and infectious diseases. VELDONA® programs include candidates for treating oral warts in HIV-positive patients, Sjögren's syndrome, and feline chronic gingivostomatitis (FCGS). Research and development activities for VELDONA® have been ongoing since the company's inception.